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Abstract
Background: The N-heptad repeat region of the HIV-1 Transmembrane Envelope protein is a
trimerization domain that forms part of a "six helix bundle" crucial to Envelope-mediated
membrane fusion. N-heptad repeat peptides have been used as extracellular reagents to inhibit
virus fusion.
Results: When expressed intracellularly with wild-type HIV-1 Envelope protein, the N-heptad
repeat domain efficiently hetero-oligomerized with Envelope and trapped it in the endoplasmic
reticulum or early Golgi, as indicated by lack of transport to the cell surface, absent proteolytic
processing, and aberrant glycosylation.
Conclusion: Post-translational processing of HIV Envelope is very sensitive to an agent that binds
to the N-heptad repeat during synthesis, suggesting that it might be possible to modify drugs that
bind to this region to have transport-blocking properties.
Background
Retroviral envelope proteins (Env) are synthesized as pre-
cursor proteins in the secretory pathway. After co-transla-
tional transfer to the endoplasmic reticulum (ER), the
envelope precursor trimerizes and becomes extensively
glycosylated. On passage through the medial- and trans-
Golgi, sugar residues are trimmed and modified, and Env
is proteolytically cleaved by a furin-like enzyme into Sur-
face (SU) and Transmembrane (TM) moieties [1-6].
Trimerization is largely determined by a ~ 30 amino acid
alpha-helical domain near the amino-terminus of TM des-
ignated the N-heptad repeat or N-helix, residues on one
side of which associate hydrophobically to form a trimeric
"coiled coil" [7-10]. In the case of HIV and related lentivi-
ruses, about 50 amino acids downstream of the N-heptad
repeat is another domain that forms an alpha-helix during
rearrangements associated with receptor-binding and
membrane fusion. This C-helix region of each Env mono-
mer folds back and binds in an anti-parallel orientation in
grooves between N-helix monomers to form a thermody-
namically stable, "6-helix bundle" whose structure has
been determined [8-10]. Formation of the 6-helix bundle
is thought to drive fusion by pulling virus and target cell
membranes together [11-16]. Subtle interactions between
helix residues that do not affect 6-helix bundle thermal
stability also impact fusion [17].
Because of their structural and mechanistic importance for
fusion, the N and C-helix regions are targets for therapeu-
tic peptides and drugs. C-helix peptides inhibit fusion at
nanomolar concentration [18-20]. Extensive structural
and mutagenesis studies have shown that they work, at
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the N-helix trimer [21-25]. Three bulky hydrophobic side
chains at one end of the C-helix fit into a deep hydropho-
bic pocket in the N-helix trimer that has been proposed as
a target for small molecule drugs[22]. N-helix peptides are
less potent fusion inhibitors, requiring micromolar con-
centration[26]. Two mechanisms have been proposed for
their action: forming homotrimers that bind viral C-heli-
ces, and forming heterotrimers with viral N-helix mono-
mers[27]. When N-helix peptides are added
extracellularly, forming heterotrimers requires peptide
exchange with monomers in pre-formed virus trimer,
which may be inefficient.
We previously reported that when Moloney-murine
leukemia virus (Mo-MLV) N-helix was expressed intracel-
lularly as a chimeric protein, it formed heterotrimers with
co-expressed wild-type Mo-MLV Env, which blocked
transport to the cell surface[28]. The heterotrimers were
apparently trapped in the ER since Env in the heterotrimer
had an immature glycosylation pattern and was not
cleaved into SU and TM, although it could be cleaved by
furin in vitro[28]. We now show that similar trapping of
HIV-1 Env occurs in cells expressing an HIV-1 N-helix-YFP
chimeric protein. The trapping is remarkably efficient as
no proteolytically cleaved, heterotrimeric molecules were
detectable by Western blot, implying that heterotrimeric
molecules do not reach the late Golgi. The strength of the
trapping suggests that small molecule drugs that bind N-
helix in the ER might be engineered to block subsequent
trafficking and thereby inhibit assembly of infectious
particles.
Results and Discussion
The amino acid sequence of the HIV N-helix is remarkably
conserved among isolates, especially in the helical wheel
"a" and "d" positions that mediate trimer association (Fig-
ure 1A). We chose a consensus sequence for the N-helix
and inserted it in frame between a signal sequence and the
yellow fluorescent protein (YFP) gene in a CMV pro-
moter-driven, cell-surface expression vector with a glyco-
sylphosphatidylinositol (gpi) membrane linkage
sequence (pYFPgpi)[29] to make pNH-YFPgpi (Figure
1B). We expected that the signal sequence in this construct
would direct the nascent N-helix to the secretory pathway
where it could interact with co-expressed HIV Envelope,
and the YPF provided a convenient tag for visualization
and immunoprecipitation (see below). HEK293 cells
transfected with this plasmid expressed YFP mainly on the
cell surface in a pattern indistinguishable from that
induced by pYFPgpi[28] (data not shown). Western blot
analysis using anti-GFP antibody showed that HEK293
cells transfected with the N-helix expression plasmid con-
tained the expected 40 kD YFP fusion protein, versus a 36
kD YFP product in cells transfected with the parent vector
lacking the N-helix insertion (Figure 1C). As noted previ-
ously[28], the parent vector, pYFPgpi, also generated a
higher molecular weight YFP species possibly due to aber-
rant glycosylation (* in figure 1C, lane 2).
To see if the N-helix-YFP fusion protein affected synthesis
or trafficking of wild-type HIV-1 Env, we co-transfected
HeLa cells with an expression vector for HIV-1 Env strain
AD8 (pAD8) plus either pNH-YFPgpi or pYFPgpi as a con-
trol. Western blot analysis of whole cell lysates using pol-
yclonal anti-gp120 (SU) antiserum showed that the N-
helix fusion protein partially inhibited processing the
gp160 Env precursor to gp120 (Figure 2A, lane 2 versus
lane 3). The total amount of Env protein was not affected.
Western blot with anti-actin antibody showed that equal
amounts of protein were loaded in all samples (Figure 2A,
left lower panel).
The partial inhibition of Env processing was associated
with a more striking inhibition of transport to the cell sur-
face, evaluated by biotinylating cell-surface proteins with
biotin-NHS, precipitating biotinylated proteins with avi-
din-agarose, and analyzing the precipitated proteins by
Western blot using anti-gp120 antiserum. Co-expressed
N-helix fusion protein markedly reduced cell surface gp-
120 (Figure 2A, lane 5 versus lane 6). Western blot using
antibody to integrin alpha5 showed that equal amounts
of biotinylated cell surface proteins were loaded in all
lanes (Figure 2A, right lower panel). The absence of a
biotinylated form of gp160 shows that the biotin label did
not attach to intracellular proteins.
The reduction in cell surface gp120 was associated with a
comparable reduction in cell fusion activity, measured
using a standard assay in which HeLa cells or HEK293
cells transfected with plasmids which express HIV-1 Tat as
well as Env were mixed with indicator HeLa-TZM cells
that express HIV receptor (CD4) and co-receptors (CXCR4
and CCR5), and contain a luciferase reporter driven by the
HIV-1 LTR. Cell fusion induced by a CXCR4-tropic Env
(derived from pNL4-3) was reduced 8- to 10-fold by co-
expression of the N-helix fusion protein, compared to co-
expression of the control YFPgpi (Figure 2B, lower panel).
Cell fusion induced by a CCR5-tropic Env (derived from
pAD8) was reduced 2–5 fold in 3 comparable experi-
ments. Lower inhibition in the case of the CCR5-tropic
Env may be due to greater expression of Env by the
pAD8Env vector compared to the pNL4-3Env vector
(unpublished observations), and/or to greater expression
of CCR5 than CXCR4 by the TZM indicator cells, which
were engineered to overexpress CCR5.
To see if the N-helix-YFP fusion protein physically associ-
ated with HIV-1 Env, we immuno-precipitated cell lysates
with anti-GFP antibody and analyzed thePage 2 of 8
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antiserum. In cells co-transfected with pNH-YFPgpi plus
the HIV-1 Env expression vector, anti-GFP antibody co-
immunoprecipitated the Env precursor gp160 but not gp-
120, even though gp120 was present in the cell lysate (Fig-
ure 3, lane 2 versus lane 1). This shows that, to the limit
of sensitivity of Western blot, all of the HIV Env that het-
ero-oligomerized with the N-helix fusion protein was pre-
vented from being processed to gp120. A similar result
was obtained in the case of MLV: the Env that co-immu-
noprecipitated with chimeric N-helix was not detectably
proteolytically processed[28]. The small amount of Env
that was processed to SU in the current experiments (Fig-
ure 3, lane 1) presumably came from wild-type Env mol-
ecules that homotrimerized rather than forming hetero-
oligomers with N-helix-YFP. In control cells co-trans-
fected with pYFPgpi instead of pNH-YFPgpi, the Env pre-
cursor was more efficiently processed to gp120, as
expected (Figure 3, lane 4 versus lane 1), and the anti-GFP
antibody did not co-immunoprecipitate HIV Env (lanes 4
and 5); the latter shows that the interaction between N-
helix-YFP and Env was not due to non-specific stickiness
of YFP.
To see if the processing defect of the Env precursor com-
plexed with N-helix-YFP was due to resistance of this form
A. Comparison of consensus amino acid sequences of N-helix regions from various HIV-1 clades, and the consensus sequence that was used to make pNH-YFPgpiFigure 1
A. Comparison of consensus amino acid sequences of N-helix regions from various HIV-1 clades, and the consensus sequence 
that was used to make pNH-YFPgpi. The letters a and d under the consensus sequence indicate the position of corresponding 
amino acids on a helical wheel. B. Schematic diagram of the coding sequence regions in expression plasmids pYFPgpi and pNH-
YFPgpi. SP, signal peptide; YFP, yellow fluorescent protein; NH, N-helix; GPI, gpi attachment signal. C. Western blot with anti-
GFP antiserum of HeLa cells transfected with pNH-YFPgpi (lane 1), pYFPgpi (lane 2), or untransfected HeLa cells (lane 3). *, 
aberrant YFPgpi product. One of three independent experiments with similar results is shown.Page 3 of 8
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Retrovirology 2005, 2:51 http://www.retrovirology.com/content/2/1/51A. Western blot analysis of HeLa cells untransfected (lanes 1, 4), or transfected with an expression vector for HIV-1 Env and Tat plus ither pNH-YFPgpi (lanes 2, 5) or pYFPgpi as control (lanes 3, 6)Figure 2
A. Western blot analysis of HeLa cells untransfected (lanes 1, 4), or transfected with an expression vector for HIV-1 Env and 
Tat plus either pNH-YFPgpi (lanes 2, 5) or pYFPgpi as control (lanes 3, 6). Left side, cell lysates analyzed with rabbit anti-gp120 
antiserum (upper panel), or anti-actin as loading control (lower panel). Right side, cell surface proteins labeled with NHS-biotin, 
precipitated with avidin-agarose, and analyzed with rabbit anti-gp120 antiserum (upper panel), or anti-integrin α5 as loading 
control (lower panel). One of two independent experiments with similar results is shown. B. Cell fusion assay. Indicator HeLa-
TZM cells (CD4+, CXCR4+, CCR5+, containing an HIV LTR-luciferase reporter) were cultured overnight with HEK293 cells 
untransfected (left bar) or transfected with an expression vector for pNL4-3 strain HIV-1 Env and Tat, plus either pNH-YFPgpi 
(middle bar) or pYFPgpi (right bar) and analyzed for luciferase activity. RLU, relative light units. One of four independent exper-
iments with similar results is shown.Page 4 of 8
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with furin enzyme. Exogenous furin cleaved the co-immu-
noprecipitated Env precursor to a species that migrated
slightly faster than native gp120 (Figure 3, lane 3 versus
lane 1). Altered mobility of the furin cleavage product is
likely due to aberrant glycosylation. In similar experi-
ments with MLV[28], the in vitro cleavage product of het-
ero-oligomerized Env treated with furin also migrated
slightly faster than normal SU, but co-migrated with SU
from cells treated with brefeldin A, a drug that disrupts the
Golgi and blocks Golgi-associated sugar modifica-
tions[30]. Since the HIV Env precursor complexed with N-
helix-YFP was cleavable in vitro but was not cleaved in vivo,
the simplest interpretation of the data is that hetero-oli-
gomerization of HIV Env gp160 with N-helix-YFP leads to
arrest of this species in the ER or cis Golgi, preventing mat-
uration of sugars and proteolytic cleavage that normally
occur in the medial and trans Golgi. It is also possible that
the hetero-oligomerized Env is misrouted to some other
furin-negative compartment.
In comparable experiments with Mo-MLV we showed that
blocking the ability of the MLV N-helix to trimerize by
substituting proline for leucine in the center of the trimer-
ization domain abolished its ability to trap Env in the ER,
providing additional evidence that oligomerization was
responsible for the trapping[28]. Further, the YFPgpi por-
tion of the chimeric N-helix did not contribute to inhibi-
tion, since the MLV N-helix linked to a 9 amino acid HA
epitope instead of YFPgpi was equally potent in trapping
MLV Env in the ER[28]. Since neither YPF nor the HA
epitope inhibit trafficking when attached to other pro-
teins, we surmise that inclusion of N-helix by itself in a
heterotrimer with Env causes misfolding.
Given the strong conservation of amino acids that direct
N-helix trimerization, it is likely that intracellular expres-
sion of an N-helix chimera would inhibit processing of all
strains of HIV. From a practical point of view, however,
the dominant negative effect of N-helix constructs is lim-
ited by their level of expression in the ER compared to that
of wild-type Env. Both the HIV and MLV N-helix-YFP
fusion proteins are efficiently transported to the cell sur-
face when expressed alone, based on the pattern of fluo-
rescence in confocal microscopy, which is mainly
restricted to the plasma membrane as previously
shown[28]. In cells co-expressing Env, there was a slight
increase in intracellular fluorescence but most of the fluo-
rescence remained on the plasma membrane, suggesting
that most N-helix-YFP molecules leave the ER before hav-
ing a chance to hetero-oligomerize with Env. To attempt
to block "premature" egress, which might reduce its abil-
ity to form a heterotrimer, we replaced the gpi attachment
peptide signal with a "KDEL" ER retention signal to make
Western blot analysis of HeLa cells transfected with an expression vector for HIV-1 Env plus either pNH-YFPgpi (lanes 1–3) or pYFPgpi as control (lanes 4–6)Figure 3
Western blot analysis of HeLa cells transfected with an expression vector for HIV-1 Env plus either pNH-YFPgpi (lanes 1–3) or 
pYFPgpi as control (lanes 4–6). Total cell lysates (lanes 1, 4) or anti-GFP immunoprecipitates (lanes 2, 3, 5, 6) were treated 
with furin (lanes 3, 6) or mock treated (lanes 1, 2, 4, 5) and analyzed with rabbit anti-gp120 antiserum.Page 5 of 8
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retained in the ER as judged by a reticular, cytoplasmic
fluorescence pattern; however, it was not more inhibitory
than the unmodified fusion protein when co-transfected
with HIV Env in a cell fusion assay (data not shown). We
also explored the effect of shortening the N-helix by delet-
ing 7 or 14 amino acids (two or four alpha-helical turns)
from either end, since short peptides can sometimes be
induced to cross cell membranes by attaching a basic
membrane transport domain[31]. However, the shorter
N-helix versions were less inhibitory in the cell fusion
assay than the full N-helix.
How do the N-helix chimeric proteins interact with HIV
Env expressed in the secretory pathway? Like extracellular
N-helix peptides, they could form heterotrimers with N-
helix regions in Env molecules[32], or homotrimerize and
then interact with C-helix regions in Env[33]. These possi-
bilities might be distinguished by seeing how mutations
in Env C-helix residues versus N-helix residues affect het-
ero-oligomerization with N-helix constructs. Extracellular
N-helix peptides preferentially bind receptor-activated
Env[33], presumably because the interacting N- or C-helix
regions are poorly exposed in the mature, unactivated
Env. Our observations imply that surfaces in Env that
interact with N-helix chimeras are exposed in nascent Env.
Our results do not exclude the possibility that N-helix-
YFPgpi also inhibits fusion by interacting with receptor-
activated Env on the cell surface.
An unexpected observation made in the course of these
studies was that the control vector pYFPgpi inhibited
fusion about ten-fold when transfected with HIV Env
expression vectors. Therefore, to evaluate the effect of the
N-helix we compared transfections with pNH-YFPgpi to
transfections with pYFPgpi. The reason for inhibition by
pYFPgpi is currently under investigation.
Conclusion
The remarkable efficacy of trapping by hetero-oligomeri-
zation suggests a drug strategy of trying to engineer small
molecules that bind the Env N-helix in the ER in a fashion
that blocks trafficking. Small molecules that bind to the
hydrophobic pocket at one end of the N-helix trimer are
under development[22,34-37]. Coupling them to an ER
retention signal like KDEL might inhibit Env trafficking.
Macrocycle drugs such as cyclosporinA act as bivalent lig-
ands that bring together two proteins, one of which can
function as an ER chaperone (e.g., cyclophilinB)[38].
Structures of several of these macrocycle-chaperone com-
plexes are known, and they show that only one side of the
macrocycle is necessary for tight (nanomolar) binding to
the chaperone[39,40]. Based on these results, it might be
possible to engineer a bi-dentate drug, one portion of
which binds in grooves of the HIV Env N-helix trimer
while another portion binds an ER chaperone, promoting
ER retention. A natural example related to this strategy
was recently described: a small molecule intermediate in
the cholesterol synthesis pathway (farnesol) that binds an
ER-associated enzyme in this pathway (HMG-CoA reduct-
ase), resulting in accelerated degradation of the
enzyme[41]. The idea we propose is the "flip side" of a
hunt for small molecules that inhibit protein misfold-
ing[42,43]. HIV Env may provide a propitious target for
drug-induced trapping since it is naturally inefficiently
processed[4] and HIV virions from several strains bear
very few Env trimers on their surface[44,45].
Materials and methods
Constructs
We aligned N-helix amino acid sequences of HIV-1 enve-
lopes in the Los Alamos database http://
www.hiv.lanl.gov/content/hiv-db/ALIGN_CURRENT/
ALIGN-INDEX.html and generated a consensus sequence
for each clade (A, B, C, D, F, G, H and O), then generated
the consensus sequence for all the clades (Fig. 1A), which
is the N-helix sequence used in this paper. Oligonucle-
otides encoding this HIV-1 N-helix with Sal I restriction
enzyme overhanging sequences were synthesized,
annealed and ligated into plasmid pYFP-gpi[29] at the Sal
I site, to generate plasmid pNH-YFPgpi (Figure 1B). The
oligonucleotide sequences used were: 5'
tcgacttctggtatagtgcagcagcagaacaatttgctgagggctattgaggcg-
caacagcatctgtt-gcaactcacagtctggggcatcaaacagctccaggcaa-
gagtcctggcg 3', and 5' tcgacgccaggactcttgcct-
ggagctgtttgatgccccagactgtgagttgcaacagatgctgttgcgcctcaatagc
cctcagcaaattgttctgctgctgcactataccagaag 3'. For expression of
T-tropic (CXCR4-using) and M-tropic (CCR5-using) HIV-
1 Env, we used plasmids pdl1443 and pAD8Env, respec-
tively, which were derived from molecular clones pNL4-3
and pAD8 by deleting 3.1 kb of gag sequences between
SphI and MscI sites [46]. These plasmids express HIV-1 Tat
as well as Env.
Transfection, surface protein labeling and cell fusion
HEK 293 or HeLa cells were co-transfected with Env-
expressing constructs pdl1443 or pAD8Env, plus pNH-
YFPgpi or pYFP-gpi as control, using Lipofectamine2000
(Invitrogen, Carlsbad, CA). Twenty four to 48 hours later,
the cells were rinsed with phosphate buffered saline (PBS)
and labeled on ice with 1 mg/ml Sulfo-NHS-LC-LC biotin
(Pierce, Rockford, IL) in PBS for one hour. After labeling,
the biotinylation reagent was quenched with 100 mM gly-
cine in PBS buffer. Following PBS wash, some of the cells
were lysed with RIPA lysis buffer (150 mM NaCl, 1% Tri-
ton X-100, 0.1% SDS, 0.5% sodium deoxycholate) for
immunoprecipitation or direct western blot, and the
remainder of the cells were co-cultivated with TZM-bl
cells[47,48] overnight and then assayed for luciferase
activity (Promega, Madison, WI) as described[28].Page 6 of 8
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blot
To immunoprecipitate cell surface biotin-labeled HIV-1
Env protein, avidin beads were directly added to the
labeled cell lysate. After binding for 2 hours with agita-
tion, beads were washed with lysis buffer and PBS, and
bound proteins eluted by boiling for 3 min in 1X SDS-
PAGE sample buffer (Invitrogen). The eluate was run on a
4–12% SDS-PAGE, transferred to PVDF membrane, and
blotted with polyclonal anti-gp120 serum (a gift from
Klaus Strebel, LMM/NIAID, made by immunizing rabbits
with purified gp120 of HIV-1 strain IIIB), or with anti-
integrin α5 (BD Transduction Lab, San Diego, CA) as a
control. To cross-immunoprecipitate intracellular HIV-1
Env protein, cell lysates were pre-cleared with normal
mouse serum and protein G Sepharose beads (Amersham,
Piscataway, NJ) for 4 hour at 4°C with agitation. The
supernatant was collected and immunoprecipitated with
monoclonal anti-GFP antibody (Clontech, Palo Alto, CA)
overnight and protein G beads for an additional 2 hours.
Beads were washed 3 times with lysis buffer and 2 times
with PBS buffer. Protein was eluted from one half of the
beads by boiling in 1X SDS-PAGE sample buffer, and the
remaining beads were re-suspended in furin reaction
buffer (0.5% triton X-100, 1 mM CaCl2, 100 mM HEPES,
1 mM β-mercaptoethanol) and treated with 0.578 mg/ml
furin (R&D systems, Minneapolis, MN) at 37°C for 16
hours as descibed[28]. The reaction was stopped and pro-
tein eluted by boiling in 1× SDS-PAGE sample buffer. The
eluted protein was analyzed by western blot using rabbit
anti-gp120 serum.
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